{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:03:24Z","timestamp":1789769004877,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T00:00:00Z","timestamp":1454976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T00:00:00Z","timestamp":1454976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00134-016-4225-7","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T05:09:40Z","timestamp":1454994580000},"page":"505-520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Antithrombin\u00a0III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Mikkel","family":"Allingstrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Wetterslev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederikke B.","family":"Ravn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Merete","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,9]]},"reference":[{"key":"4225_CR1","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1097\/CCM.0b013e318186aec8","volume":"36","author":"H Wunsch","year":"2008","unstructured":"Wunsch H, Angus D, Harrison D et al (2008) Variation in critical care services across North America and Western Europe. Crit Care Med 36:2787\u20132793","journal-title":"Crit Care Med"},{"key":"4225_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/07853890310017251","volume":"36","author":"M Levi","year":"2004","unstructured":"Levi M, De Jonge E, Van der Poll T (2004) New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 36:41\u201349","journal-title":"Ann Med"},{"key":"4225_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4161\/viru.27372","volume":"5","author":"F Mayr","year":"2014","unstructured":"Mayr F, Yende S, Angus D (2014) Epidemiology of severe sepsis. Virulence 5:4\u201311","journal-title":"Virulence"},{"key":"4225_CR4","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1517\/14656566.1.6.1203","volume":"1","author":"P Periti","year":"2000","unstructured":"Periti P (2000) Current treatment of sepsis and endotoxaemia. Expert Opin Pharmacother 1:1203\u20131217","journal-title":"Expert Opin Pharmacother"},{"key":"4225_CR5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(04)16259-4","volume":"363","author":"KH Polderman","year":"2004","unstructured":"Polderman KH, Girbes ARJ (2004) Drug intervention trials in sepsis: divergent results. Lancet 363:1721\u20131723","journal-title":"Lancet"},{"key":"4225_CR6","first-page":"160","volume":"89","author":"BF Becker","year":"2000","unstructured":"Becker BF, Heindl B, Kupatt C, Zahler S (2000) Endothelial function and hemostasis. Z Kardiol 89:160\u2013167","journal-title":"Z Kardiol"},{"key":"4225_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jpeds.2015.06.006","volume":"167","author":"R Diaz","year":"2015","unstructured":"Diaz R, Moffett BS, Karabinas S et al (2015) Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis. J Pediatr 167:645\u2013649","journal-title":"J Pediatr"},{"key":"4225_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/00003246-200205001-00024","volume":"30","author":"SM Opal","year":"2002","unstructured":"Opal SM, Kessler CM, Roemisch J, Knaub S (2002) Antithrombin, heparin, and heparan sulfate. Crit Care Med 30:325\u2013331","journal-title":"Crit Care Med"},{"key":"4225_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/cc1529","volume":"6","author":"D Rublee","year":"2002","unstructured":"Rublee D, Opal SM, Schramm W et al (2002) Quality of life effects of antithrombin\u00a0III in sepsis survivors: results from the KyberSept trial. Crit Care 6:349\u2013356","journal-title":"Crit Care"},{"key":"4225_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","volume":"43","author":"R Zarychanski","year":"2015","unstructured":"Zarychanski R, Abou-Setta AM, Kanji S et al (2015) The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med 43:511\u2013518","journal-title":"Crit Care Med"},{"key":"4225_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"4225_CR12","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"4225_CR13","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http:\/\/www.cochrane-handbook.org. Accessed March 2011"},{"issue":"3","key":"4225_CR14","first-page":"5370","volume":"16","author":"A Afshari","year":"2008","unstructured":"Afshari A, Wetterslev J, Brok J, M\u00f8ller A (2008) Antithrombin\u00a0III for critically ill patients. Cochrane Database Syst Rev 16(3):5370","journal-title":"Cochrane Database Syst Rev"},{"key":"4225_CR15","unstructured":"The Cochrane Collaboration (2014) Review Manager (RevMan), version 5.3.5. The Nordic Cochrane Centre, Copenhagen"},{"key":"4225_CR16","unstructured":"Thorlund K, Engstr\u00f8m J, Wetterslev J, Brok J, Imberger G, Gluud C (2011) User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, pp 1\u2013115. http:\/\/www.ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"key":"4225_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1399-6576.1992.tb03557.x","volume":"36","author":"J Albert","year":"1992","unstructured":"Albert J, Blomqvist H, Gardlund B et al (1992) Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand 36:745\u2013752","journal-title":"Acta Anaesthesiol Scand"},{"key":"4225_CR18","first-page":"17","volume":"21","author":"RA Balk","year":"1995","unstructured":"Balk RA, Bedrosian C, McCormick L et al (1995) Prospective double blind placebo-controlled trial of ATIII substitution in sepsis. Intensive Care Med 21:17","journal-title":"Intensive Care Med"},{"key":"4225_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0049-3848(92)90099-V","volume":"68","author":"F Baudo","year":"1992","unstructured":"Baudo F, DeGasperi A, De Cataldo F et al (1992) Antithrombin\u00a0III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thromb Res 68:409\u2013416","journal-title":"Thromb Res"},{"key":"4225_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s001340050576","volume":"24","author":"F Baudo","year":"1998","unstructured":"Baudo F, Caimi TM, De Cataldo F et al (1998) Antithrombin\u00a0III (ATIII) replacement therapy in patients with severe sepsis and\/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 24:336\u2013342","journal-title":"Intensive Care Med"},{"key":"4225_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0049-3848(85)90123-9","volume":"39","author":"B Blauhut","year":"1985","unstructured":"Blauhut B, Kramar H, Vinazzer H, Bergmann H (1985) Substitution of antithrombin\u00a0III in shock and DIC: a randomized study. Thromb Res 39:81\u201389","journal-title":"Thromb Res"},{"key":"4225_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/BF01705725","volume":"20","author":"JM Diaz-Cremades","year":"1994","unstructured":"Diaz-Cremades JM, Lorenzo R, S\u00e1nchez M et al (1994) Use of antithrombin\u00a0III in critical patients. Intensive Care Med 20:577\u2013580","journal-title":"Intensive Care Med"},{"key":"4225_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s001340050642","volume":"24","author":"B Eisele","year":"1998","unstructured":"Eisele B, Lamy M, Thijs LG et al (1998) Antithrombin\u00a0III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin\u00a0III in severe sepsis. Intensive Care Med 24:663\u2013672","journal-title":"Intensive Care Med"},{"key":"4225_CR24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1378\/chest.104.3.882","volume":"104","author":"F Fourrier","year":"1993","unstructured":"Fourrier F, Chopin C, Huart JJ et al (1993) Double-blind, placebo-controlled trial of antithrombin\u00a0III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882\u2013888","journal-title":"Chest"},{"key":"4225_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000067005","volume":"83","author":"F Fulia","year":"2003","unstructured":"Fulia F, Cordaro S, Meo P et al (2003) Can the administration of antithrombin\u00a0III decrease the risk of cerebral hemorrhage in premature infants. Biol Neonate 83:1\u20135","journal-title":"Biol Neonate"},{"key":"4225_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/cc13163","volume":"17","author":"S Gando","year":"2013","unstructured":"Gando S, Saitoh D, Ishikura H et al (2013) A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 17:297","journal-title":"Crit Care"},{"key":"4225_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00008506-200101000-00010","volume":"13","author":"A Grenander","year":"2001","unstructured":"Grenander A, Bredbacka S, Rydvall A et al (2001) Antithrombin treatment in patients with traumatic brain injury: a pilot study. J Neurosurg Anesthesiol 13:49\u201356","journal-title":"J Neurosurg Anesthesiol"},{"key":"4225_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S1083-8791(98)50003-1","volume":"4","author":"WD Haire","year":"1998","unstructured":"Haire WD, Ruby EI, Stephens LC et al (1998) A prospective randomized double-blind trial of antithrombin\u00a0III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 4:142\u2013150","journal-title":"Biol Blood Marrow Transplant"},{"key":"4225_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-3148.1991.tb00020.x","volume":"1","author":"PL Harper","year":"1991","unstructured":"Harper PL, Williamson L, Park G et al (1991) A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfus Med 1:121\u2013128","journal-title":"Transfus Med"},{"key":"4225_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/00024382-199711000-00003","volume":"8","author":"D Inthorn","year":"1997","unstructured":"Inthorn D, Hoffmann JN, Hartl WH et al (1997) Antithrombin\u00a0III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 8:328\u2013334","journal-title":"Shock"},{"key":"4225_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1055\/s-2004-815632","volume":"29","author":"T Kobayashi","year":"2003","unstructured":"Kobayashi T, Terao T, Ikenoue T et al (2003) Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost 29:645\u2013652","journal-title":"Semin Thromb Hemost"},{"key":"4225_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0168-8278(05)80213-2","volume":"17","author":"PG Langley","year":"1993","unstructured":"Langley PG, Hughes RD, Forbes A et al (1993) Controlled trial of antithrombin\u00a0III supplementation in fulminant hepatic failure. J Hepatol 17:326\u2013331","journal-title":"J Hepatol"},{"key":"4225_CR33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1160\/TH07-11-0684","volume":"100","author":"A Lavrentieva","year":"2008","unstructured":"Lavrentieva A, Kontakiotis T, Bitzani M et al (2008) The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost 100:286\u2013290","journal-title":"Thromb Haemost"},{"key":"4225_CR34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1055\/s-0037-1614071","volume":"84","author":"M Maki","year":"2000","unstructured":"Maki M, Kobayashi T, Terao T et al (2000) Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. Thromb Haemost 84:583\u2013590","journal-title":"Thromb Haemost"},{"key":"4225_CR35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1160\/TH02-11-0283","volume":"90","author":"L Mitchell","year":"2003","unstructured":"Mitchell L, Andrew M, Hanna K et al (2003) Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 90:235\u2013244","journal-title":"Thromb Haemost"},{"key":"4225_CR36","first-page":"288","volume":"62","author":"W Muntean","year":"1989","unstructured":"Muntean W, Rossegger H (1989) Antithrombin\u00a0III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thromb Haemost 62:288","journal-title":"Thromb Haemost"},{"key":"4225_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.15360\/1813-9779-2008-5-49","volume":"5","author":"E Neporada","year":"2008","unstructured":"Neporada E, Vorobyeva N, Nedashkovsky E (2008) Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatol 5:49\u201354","journal-title":"Obshaya Reanimatol"},{"key":"4225_CR38","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.ajem.2011.06.003","volume":"30","author":"T Nishiyama","year":"2012","unstructured":"Nishiyama T, Kohno Y, Koishi K (2012) Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. Am J Emerg Med 30:1219\u20131223","journal-title":"Am J Emerg Med"},{"key":"4225_CR39","first-page":"1251","volume":"73","author":"G Palareti","year":"1995","unstructured":"Palareti G, Legnani C, Coccheri S et al (1995) Laboratory effects of antithrombin-III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support\u2014a controlled, double-blind, randomized multicenter study. Thromb Haemost 73:1251","journal-title":"Thromb Haemost"},{"key":"4225_CR40","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1164\/ajrccm.158.2.9712116","volume":"158","author":"B Schmidt","year":"1998","unstructured":"Schmidt B, Gillie P, Mitchell L et al (1998) A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 158:470\u2013476","journal-title":"Am J Respir Crit Care Med"},{"key":"4225_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1046\/j.1365-2362.2000.00630.x","volume":"30","author":"M Schorr","year":"2000","unstructured":"Schorr M, Siebeck M, Zugel N et al (2000) Antithrombin\u00a0III and local serum application: adjuvant therapy in peritonitis. Eur J Clin Invest 30:359\u2013366","journal-title":"Eur J Clin Invest"},{"issue":"Suppl 1","key":"4225_CR42","first-page":"76","volume":"23","author":"HP Schuster","year":"1997","unstructured":"Schuster HP, Eisele B, Keinecke HO et al (1997) S-AT\u00a0III study: antithrombin\u00a0III in patients with sepsis. Intensive Care Med 23(Suppl 1):76","journal-title":"Intensive Care Med"},{"key":"4225_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/tcic.7.6.291.296","volume":"7","author":"N Smith-Erichsen","year":"1996","unstructured":"Smith-Erichsen N, Aasen AO, Kongsgaard UE et al (1996) The effect of antithrombin\u00a0III substitution therapy on components of the plasma protease systems in surgical patients. Clin Intensive Care 7:291\u2013296","journal-title":"Clin Intensive Care"},{"key":"4225_CR44","first-page":"42","volume":"2","author":"N Vorobyeva","year":"2007","unstructured":"Vorobyeva N, Neporada E, Turundaevskaia O, Mel\u2019nikova G (2007) Place of antithrombin\u00a0III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziol Reanimatol 2:42\u201344","journal-title":"Anesteziol Reanimatol"},{"key":"4225_CR45","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","volume":"286","author":"BL Warren","year":"2001","unstructured":"Warren BL, Eid A, Singer P et al (2001) Caring for the critically ill patient. High-dose antithrombin\u00a0III in severe sepsis, a randomized controlled trial. JAMA 286:1869\u20131878","journal-title":"JAMA"},{"key":"4225_CR46","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1097\/00005373-199811000-00015","volume":"45","author":"C Waydhas","year":"1998","unstructured":"Waydhas C, Nast-Kolb D, Gippner-Steppert\n C et al (1998) High-dose antithrombin\u00a0III treatment of severely injured patients: results of a prospective study. J Trauma 45:931\u2013940","journal-title":"J Trauma"},{"key":"4225_CR47","unstructured":"D\u2019Angelo A, Valsecchi L (2015) High-dose antithrombin supplementation in early pre-eclampsia: a double-blind, placebo controlled study (on behalf of the AT\u00a0III-EPAS study group). http:\/\/abstract.mci-group.com\/cgi-bin\/mc\/printabs.pl?APP=ISTH2009ABS-abstract&TEMPLATE=&keyf=0771&showHide=show&client. Accessed 21 April 2015"},{"key":"4225_CR48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/bmj.321.7261.585","volume":"321","author":"PC Gotzsche","year":"2000","unstructured":"Gotzsche PC (2000) Why we need a broad perspective on meta-analysis. It may be crucially important for patients. BMJ 321:585\u2013586","journal-title":"BMJ"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-016-4225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-016-4225-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-016-4225-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-016-4225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:41:20Z","timestamp":1744159280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-016-4225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,9]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["4225"],"URL":"https:\/\/doi.org\/10.1007\/s00134-016-4225-7","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,9]]},"assertion":[{"value":"9 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Mikkel Allingstrup, Frederikke B. Ravn, Ann Merete M\u00f8ller and Arash Afshari declare that there are no conflicts of interest. J\u00f8rn Wetterslev declares that he is a member of the task force on TSA at Copenhagen Trial Unit developing and programming TSA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}